Alnylam Pharmaceuticals (ALNY) Other Non-Current Liabilities (2009 - 2026)

Alnylam Pharmaceuticals has reported Other Non-Current Liabilities for 17 years, with the latest figure at $7.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 98.2% year-over-year to $7.6 million; the trailing twelve-month figure through Mar 2026 stood at $7.6 million (down 98.2% YoY), and the FY2025 full-year result was $7.6 million, down 98.07% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $7.6 million, roughly flat from $7.6 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $439.7 million in Q3 2025, with the low at $7.6 million in Q4 2025.
• Historically, Other Non-Current Liabilities has averaged $261.8 million across 5 years, with a median of $280.7 million in 2023.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities surged 139.37% — and 2026, when it slumped 98.2%.
• Alnylam Pharmaceuticals' Other Non-Current Liabilities stood at $212.6 million in 2022, then soared by 45.09% to $308.4 million in 2023, then advanced by 27.46% to $393.1 million in 2024, then slumped by 98.07% to $7.6 million in 2025, then climbed by 0.22% to $7.6 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $7.6 million (Q1 2026), $7.6 million (Q4 2025), and $439.7 million (Q3 2025), per Business Quant data.